Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis

Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui, Di Huang, Ziwei Huang, Zhaozhen Wu, Yi Hu, Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui, Di Huang, Ziwei Huang, Zhaozhen Wu, Yi Hu

Abstract

Background: Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have demonstrated promise in treating a variety of advanced cancers; however, little is known regarding their efficacy under various clinical situations, including different cancer types, treatment lines, drug combinations, and therapeutic regimens.

Methods: Published articles and conference abstracts (in English) in PubMed, Embase, the Cochrane Central Register, and Web of Science were searched up to February 10, 2020. The data were analyzed by the meta-analysis program in Stata.

Results: A total of 16,400 patients from 91 clinical trials were included in this meta-analysis. PD-1/PD-L1 inhibitors had a mean ORR of 19.56% (95% CI: 15.09-24.03), a median TTR of 2.05 months (m) (95%CI: 1.85-2.26), and a median DOR of 10.65 m (95%CI: 7.78-13.52). First-line treatment had a higher ORR (36.57% vs. 13.18%) but a shorter DOR (9.00 m vs. 13.42 m) compared to the second-line or subsequent treatment. Immunotherapy combined with chemotherapy (I+C) (46.81% [95%CI: 36.02-57.60]) had a statistically significant higher ORR compared to immunotherapy (I) (17.75% [95%CI: 14.47-21.03]) or immunotherapy combined with immunotherapy (I+O) (12.25% [95%CI: 1.56-22.94]), while I+C (8.09 m [95%CI: 6.86-9.32]) appeared to reduce the DOR compared to I (12.39 m [95%CI: 7.60-17.18]). PD-1 inhibitors were associated with better ORR (21.65% vs. 17.60%) and DOR (11.26 m vs. 10.03 m) compared to PD-L1 inhibitors. There were no significant differences in TTR under different situations.

Conclusions: PD-1/PD-L1 inhibitors were promising immunotherapeutic agents to achieve satisfactory response efficacies with different cancer types, treatment lines, drug combinations, and therapeutic regimens. This comprehensive summary of the response efficacy of PD-1/PD-L1 inhibitors serves as a reference for clinicians to make evidence-based decisions.

Keywords: PD-1/PD-L1 inhibitors; duration of response; meta-analysis; objective response rate; response efficacy; time to response.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Chen, Zhang, Zheng, Tao, Zhang, Ma, Liu, Wang, Qian, Cui, Huang, Huang, Wu and Hu.

Figures

Figure 1
Figure 1
Flow diagram of the literature search and trial selection process.
Figure 2
Figure 2
Forest plot for objective response rate (ORR) by cancer type (A), treatment line (B), drug combination (C), and therapeutic regimen (D). Squares represent the study-specific effect size (ORR). The area of the square is inversely proportional to the standard error of the study (and therefore indirectly to the sample size), and a larger area indicates greater weight in the calculation of the pooled effect size. The horizontal line crossing the square represents the 95% CI. The diamonds represent the estimated overall effect based on the meta-analysis. CI, confidence interval.
Figure 3
Figure 3
Forest plot for time to response (TTR) by cancer type (A), treatment line (B), drug combination (C), and therapeutic regimen (D). Squares represent the study-specific effect size (TTR). The area of a square is inversely proportional to the standard error of the study (and therefore indirectly to the sample size), and a larger area indicates greater weight in the calculation of the pooled effect size. The horizontal line crossing the square represents the 95% CI. The diamonds represent the estimated overall effect based on the meta-analysis. CI, confidence interval.
Figure 4
Figure 4
Forest plot for duration of response (DOR) by cancer type (A), treatment line (B), drug combination (C), and therapeutic regimen (D). Squares represent study-specific effect sizes (DOR). The area of a square is inversely proportional to the standard error of the study (and therefore indirectly to the sample size), and a larger area indicates greater weight in the calculation of the pooled effect size. The horizontal line crossing the square represents the 95% CI. The diamonds represent the estimated overall effect based on the meta-analysis. CI, confidence interval.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2018) 68(6):394–424. 10.3322/caac.21492
    1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (2018) 359(6382):1350–5. 10.1126/science.aar4060
    1. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol (2018) 8:86. 10.3389/fonc.2018.00086
    1. Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Cranio Maxill Surg (2011) 39(2):91–2. 10.1016/j.jcms.2010.11.001
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials (1986) 7(3):177–88. 10.1016/0197-2456(86)90046-2
    1. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol (2005) 5(1):13. 10.1186/1471-2288-5-13
    1. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol (2014) 14(1):135. 10.1186/1471-2288-14-135
    1. Chen C, Zhang F, Zhou N, Gu Y-M, Zhang Y-T, He Y-D, et al. . Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. OncoImmunology (2019) 8(5):e1581547. 10.1080/2162402X.2019.1581547
    1. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. . Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med (2018) 379(21):2040–51. 10.1056/nejmoa1810865
    1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. . Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med (2018) 378(22):2078–92. 10.1056/NEJMoa1801005
    1. Cappuzzo F, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter H, et al. . LBA53 IMpower130: progression-free survival (PFS) and safety analysis from a randomised Phase III study of carboplatin+ nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Ann Oncol (2018) 29(suppl_8):mdy424. 065. 10.1093/annonc/mdy424.065
    1. Jotte RM, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Abreu DR, Hussein MA, et al. . IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab+ carboplatin+ paclitaxel or nab-paclitaxel vs carboplatin+ nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol (2018) 36(18 suppl):LBA9000. 10.1200/JCO.2018.36
    1. Papadimitrakopoulou V, Cobo M, Bordoni R, Dubray-Longeras P, Szalai Z, Ursol G, et al. . IMPOWER132: PFS and safety results with 1L atezolizumab+ carboplatin/cisplatin+ pemetrexed in stage IV non-squamous NSCLC. J Thorac Oncol (2018) 13(10):S332–33. 10.1016/j.jtho.2018.08.262
    1. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. . Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med (2018) 378(24):2288–301. 10.1056/nejmoa1716948
    1. Borghaei H, Hellmann MD, Paz-Ares LG, Ramalingam SS, Reck M, O’Byrne KJ, et al. . Nivolumab (Nivo)+ platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with< 1% tumor PD-L1 expression: Results from CheckMate 227. ASCO (2018) 36(15_suppl):9001. 10.1200/JCO.2018.36.15_suppl.9001
    1. Hellmann MD, Ciuleanu T-E, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. . Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med (2018) 378(22):2093–104. 10.1056/NEJMoa1801946
    1. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. . Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med (2015) 372(21):2018–28. 10.1056/NEJMoa1501824
    1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2015) 372(4):320–30. 10.1056/NEJMoa1412082
    1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. . Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med (2016) 375(19):1823–33. 10.1056/NEJMoa1606774
    1. Mok TS, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet (2019) 393(10183):1819–30. 10.1016/S0140-6736(18)32409-7
    1. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. . First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J Med (2017) 376(25):2415–26. 10.1097/01.COT.0000525227.51402.c5
    1. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet (2017) 389(10088):2492–502. 10.1016/S0140-6736(17)31046-2
    1. Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL, et al. . Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol (2018) 19(11):1480–92. 10.1016/S1470-2045(18)30700-9
    1. Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, et al. . First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol (2017) 18(11):1483–92. 10.1016/S1470-2045(17)30616-2
    1. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. . Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet (2017) 389(10064):67–76. 10.1016/S0140-6736(16)32455-2
    1. Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord J-P, et al. . Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol (2019) 5(2):195–203. 10.1001/jamaoncol.2018.4628
    1. D’Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob J-J, et al. . Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol (2018) 4(9):e180077–e. 10.1001/jamaoncol.2018.0077
    1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. . Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med (2015) 373(17):1627–39. 10.1056/NEJMoa1507643
    1. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. . Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med (2015) 373(2):123–35. 10.1056/NEJMoa1504627
    1. Wu Y-L, Lu S, Cheng Y, Zhou C, Wang J, Mok T, et al. . Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. J Thorac Oncol (2019) 14(5):867–75. 10.1016/j.jtho.2019.01.006
    1. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. . Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (2016) 387(10030):1837–46. 10.1016/S0140-6736(16)00587-0
    1. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Von Pawel J, et al. . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (2017) 389(10066):255–65. 10.1016/S0140-6736(16)32517-X
    1. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. . Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer. J Clin Oncol (2015) 33(18):2004–12. 10.1200/JCO.2014.58.3708
    1. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. . Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol (2015) 16(3):257–65. 10.1016/S1470-2045(15)70054-9
    1. Lee JS, Lee KH, Cho EK, Kim DW, Kim SW, Kim JH, et al. . Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. Lung Cancer (2018) 122:234–42. 10.1016/j.lungcan.2018.05.023
    1. Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, et al. . Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer (2018) 101:201–9. 10.1016/j.ejca.2018.06.031
    1. Garassino MC, Cho B-C, Kim J-H, Mazières J, Vansteenkiste J, Lena H, et al. . Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol (2018) 19(4):521–36. 10.1016/S1470-2045(18)30144-X
    1. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. . Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 32(10):1020–30. 10.1200/JCO.2013.53.0105
    1. McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, et al. . Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol (2015) 33(18):2013–20. 10.1200/JCO.2014.58.1041
    1. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. . Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med (2015) 373(19):1803–13. 10.1056/NEJMoa1510665
    1. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. . Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol (2015) 33(13):1430–7. 10.1200/JCO.2014.59.0703
    1. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol (2016) 17(7):883–95. 10.1016/S1470-2045(16)30098-5
    1. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. . Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med (2016) 375(19):1856–67. 10.1056/NEJMoa1602252
    1. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, et al. . Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol (2016) 17(11):1590–8. 10.1016/S1470-2045(16)30496-X
    1. Weber J, Gibney G, Kudchadkar R, Yu B, Cheng P, Martinez AJ, et al. . Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res (2016) 4(4):345–53. 10.1158/2326-6066.CIR-15-0193
    1. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. . Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol (2016) 34(21):2460–7. 10.1200/JCO.2015.64.8931
    1. Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, et al. . Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (2017) 390(10111):2461–71. 10.1016/S0140-6736(17)31827-5
    1. Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, et al. . Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol (2017) 18(5):631–9. 10.1016/S1470-2045(17)30181-X
    1. Larkin J, Minor D, D’Angelo S, Neyns B, Smylie M, Miller WH, et al. . Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol (2018) 36(4):383–90. 10.1200/JCO.2016.71.8023
    1. Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, et al. . Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol (2019) 14(2):237–44. 10.1016/j.jtho.2018.10.003
    1. Maruyama D, Hatake K, Kinoshita T, Fukuhara N, Choi I, Taniwaki M, et al. . Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Sci (2017) 108(5):1007–12. 10.1111/cas.13230
    1. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, et al. . Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol (2017) 18(4):446–53. 10.1016/S1470-2045(17)30104-3
    1. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. . Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol (2018) 36(14):1428–39. 10.1200/JCO.2017.76.0793
    1. D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. . Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol (2018) 19(3):416–26. 10.1016/S1470-2045(18)30006-8
    1. Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, et al. . CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol (2018) 36(28):2836–44. 10.1200/JCO.2017.76.6212
    1. Ma BB, Lim W-T, Goh B-C, Hui EP, Lo K-W, Pettinger A, et al. . Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic phase 2 consortium (NCI-9742). J Clin Oncol (2018) 36(14):1412–8. 10.1200/JCO.2017.77.0388
    1. Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, et al. . Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol (2018) 13(10):1569–76. 10.1016/j.jtho.2018.05.038
    1. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. . PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med (2015) 372(26):2509–20. 10.1056/NEJMoa1500596
    1. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. . Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med (2015) 372(26):2521–32. 10.1056/NEJMoa1503093
    1. Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. . Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol (2016) 34(32):3838–45. 10.1200/JCO.2016.68.1478
    1. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol (2016) 17(6):717–26. 10.1016/S1470-2045(16)00175-3
    1. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. . Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol (2016) 17(7):956–65. 10.1016/S1470-2045(16)30066-3
    1. Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. . Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol (2017) 18(5):623–30. 10.1016/S1470-2045(17)30169-9
    1. Bellmunt J, De Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al. . Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med (2017) 376(11):1015–26. 10.1056/NEJMoa1613683
    1. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, et al. . Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol (2017) 35(14):1542–9. 10.1200/JCO.2016.70.1524
    1. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H-J, Morse MA, et al. . Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol (2017) 18(9):1182–91. 10.1016/S1470-2045(17)30422-9
    1. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol (2017) 18(3):312–22. 10.1016/S1470-2045(17)30065-7
    1. Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M, et al. . Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. J Clin Oncol (2018) 36(1):61–7. 10.1200/JCO.2017.74.9846
    1. Frenel J-S, Le Tourneau C, O’Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, et al. . Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol (2017) 35(36):4035–41. 10.1200/JCO.2017.74.5471
    1. Hsu C, Lee S-H, Ejadi S, Even C, Cohen RB, Le Tourneau C, et al. . Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study. J Clin Oncol (2017) 35(36):4050–6. 10.1200/JCO.2017.73.3675
    1. Lukas RV, Rodon J, Becker K, Wong ET, Shih K, Touat M, et al. . Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol (2018) 140(2):317–28. 10.1007/s11060-018-2955-9
    1. Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, et al. . Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: long-term outcomes from a phase 1 study. JAMA Oncol (2018) 4(4):537–44. 10.1001/jamaoncol.2017.5440
    1. Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, et al. . Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Invest New Drugs (2016) 34(3):347–54. 10.1007/s10637-016-0347-6
    1. Powles T, Durán I, Van Der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2018) 391(10122):748–57. 10.1016/S0140-6736(17)33297-X
    1. Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, et al. . Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study. J Clin Oncol (2017) 35(19):2117. 10.1200/JCO.2016.71.6795
    1. Bang Y-J, Ruiz EY, Van Cutsem E, Lee K-W, Wyrwicz L, Schenker M, et al. . Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol (2018) 29(10):2052–60. 10.1093/annonc/mdy264
    1. Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau H-T, Forero-Torres A, et al. . Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat (2018) 167(3):671–86. 10.1007/s10549-017-4537-5
    1. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. . Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol (2016) 34(26):3119–25. 10.1200/JCO.2016.67.9761
    1. Powles T, O’donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ, et al. . Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol (2017) 3(9):e172411. 10.1001/jamaoncol.2017.2411
    1. O’Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. . Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PloS One (2017) 12(12):e0189848. 10.1371/journal.pone.0189848
    1. Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J, et al. . Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol (2017) 18(2):212–20. 10.1016/S1470-2045(17)30007-4
    1. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. . Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol (2017) 18(11):1493–501. 10.1016/S1470-2045(17)30624-1
    1. Yamazaki N, Takenouchi T, Fujimoto M, Ihn H, Uchi H, Inozume T, et al. . Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemother Pharmacol (2017) 79(4):651–60. 10.1007/s00280-016-3237-x
    1. Adams S, Schmid P, Rugo H, Winer E, Loirat D, Awada A, et al. . Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol (2018) 30(3):397–404. 10.1093/annonc/mdy517
    1. Cohen RB, Delord J-P, Doi T, Piha-Paul SA, Liu SV, Gilbert J, et al. . Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol (2018) 41(11):1083–8. 10.1097/COC.0000000000000429
    1. Cohen EE, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. . Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet (2019) 393(10167):156–67. 10.1016/S0140-6736(18)31999-8
    1. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. . Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol (2018) 4(5):e180013. 10.1001/jamaoncol.2018.0013
    1. Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, et al. . Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol (2018) 19(3):347–55. 10.1016/S1470-2045(18)30062-7
    1. Hansen A, Massard C, Ott P, Haas N, Lopez J, Ejadi S, et al. . Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol (2018) 29(8):1807–13. 10.1093/annonc/mdy232
    1. Rugo HS, Delord J-P, Im S-A, Ott PA, Piha-Paul SA, Bedard PL, et al. . Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer. Clin Cancer Res (2018) 24(12):2804–11. 10.1158/1078-0432.CCR-17-3452
    1. Shitara K, Özgüroğlu M, Bang Y-J, Di Bartolomeo M, Mandalà M, Ryu M-H, et al. . Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet (2018) 392(10142):123–33. 10.1016/S0140-6736(18)31257-1
    1. Zhu A, Finn R, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. . KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol (2018) 19(7):940–52. 10.1016/S1470-2045(18)30351-6
    1. McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, et al. . Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol (2016) 34(8):833–42. 10.1200/JCO.2015.63.7421
    1. Rosenberg JE, Hoffman-Censits J, Powles T, Van Der Heijden MS, Balar AV, Necchi A, et al. . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (2016) 387(10031):1909–20. 10.1016/S0140-6736(16)00561-4
    1. Colevas A, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau N, et al. . Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol (2018) 29(11):2247–53. 10.1093/annonc/mdy411
    1. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2016) 387(10027):1540–50. 10.1016/S0140-6736(15)01281-7
    1. Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, et al. . Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol (2017) 35(22):2535–41. 10.1200/JCO.2017.72.5952
    1. Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. . Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol (2019) 5(1):74–82. 10.1001/jamaoncol.2018.4224
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12(4):252–64. 10.1038/nrc3239
    1. Ribas A. Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov (2015) 5:915–9. 10.1158/-15-0563
    1. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. . Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5:200ra116. 10.1126/scitranslmed.3006504
    1. Kuryk L, Bertinato L, Staniszewska M, Pancer K, Wieczorek M, Salmaso S, et al. . From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. Cancers (Basel) (2020) 12(10):3057. 10.3390/cancers12103057
    1. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. . Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell (2017) 170(6):1109–19.e10. 10.1016/j.cell.2017.08.027
    1. Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov (2019) 18(9):689–706. 10.1038/s41573-019-0029-0
    1. Chowdhury P, Chamoto K, Honjo T. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J Intern Med (2018) 283(2):110–20. 10.1111/joim.12708
    1. Song W, Shen L, Wang Y, Liu Q, Goodwin TJ, Li J, et al. . Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun (2018) 9(1):2237. 10.1038/s41467-018-04605-x

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere